Locations:
Search IconSearch
August 6, 2014/Cancer/Radiation Oncology

Gamma Knife® Now Option for More Brain Metastases

Higher isodose safe and efficient for 6 to 10 lesions

gamma-knife_690x380

As Gamma Knife® technology gained simplicity and automation, radiation oncologists and neurosurgeons gained the opportunity to treat more brain metastases, but it came at the cost of patient comfort during lengthier sessions. Now, Cleveland Clinic physicians have verified the safety of a faster treatment method, opening Gamma Knife as an option for patients with up to 10 or more brain metastases.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

In 2007, Cleveland Clinic acquired the Gamma Knife® Perfexion system, which is the most updated version of the system, allowing for the treatment of multiple lesions in one setup. This led to a paradigm shift in how we treat the brain, explains Samuel Chao, MD, radiation oncologist at Cleveland Clinic Taussig Cancer Institute. Gamma Knife® used to be applied traditionally for one to three brain metastases.

“With the newer Perfexion system, we could treat more brain metastases, and more efficiently than in the past,” says Dr. Chao. The one drawback is that when treating more lesions the patient has to remain on the treatment table for three to four hour (for six to 10 lesions), which can be extremely uncomfortable, especially for a patient with various discomfort and limitations from the disease’s effects, or other disorders, says Dr. Chao.

Faster Treatment
He verified a solution, though, in a recently published Neurosurgery study. Radiation oncologists and neurosurgeons typically used a 50 to 60 percent isodose line prior to this study. However, a 70 or more percent isodose line achieves the same results in less time. Using the higher isodose line has been applied for many years in linear accelerators to safely and effectively treat other parts of the body including the brain, but had not been verified as safe with Gamma Knife® to treat the brain. Dr. Chao wanted to explore this possibility, for effectiveness and safety, including any side effects.
“We had hypothesized that we could use the higher isodose line without compromising control or causing side effects, especially given its successful use with linear accelerators. This study confirms it,” says Dr. Chao.

Advertisement

Patient Advantages
Six to 10 lesions can be treated in two to three hours with the higher isodose line. The Perfexion system positioning is all automated and aligns perfectly, which enhances safety compared to prior systems with manual alignment. This provides additional safety insurance with the higher isodose line. Patients are more comfortable, have less time invested in the appointment, and most importantly, have a new treatment option to consider.

Previously, many patients would have instead opted for whole brain radiation. This is still an appropriate course for some patients, but for many this study opens a more targeted option to try prior to whole brain radiation without as high a risk of side effects such as memory loss. Other patients may have already received their lifetime maximum exposure to whole brain radiation and would previously have had no effective course of treatment. This offers a new treatment course and hope for these individuals, which Dr. Chao is already seeing applied in practice.
In addition to Gamma Knife®, Cleveland Clinic recently added an EDGE™ radiosurgery suite, building out a comprehensive line of aggressive radiation therapy options, especially for sites outside of the brain such as spine, lung, liver, kidney, and prostate.

Advertisement

Related Articles

Plan of care meeting
October 4, 2024/Cancer/Radiation Oncology
Five Years of Parallel Prospective Plan of Care Reviews

Radiation oncology department finds weekly plan of care meetings have multiple benefits

Spine cancer
September 30, 2024/Cancer/Radiation Oncology
New Study Supports SBRT as Safe, Effective for Osteosarcoma

Research highlights promising outcomes for treating recurrent and metastatic cases

22-CNR-3127708-CQD-Hero2-650×450-credits
November 22, 2023/Cancer/Radiation Oncology
A Germline Biomarker Offers Insight Into Treatment Selection for Men With Prostate Cancer

Correlation found between the biomarker HSD3B1 and resistance to combined hormone therapy and radiotherapy

23-CNR-4164208 ASTRO 2023 graphic CQD
September 21, 2023/Cancer/Radiation Oncology
Top 10 Presentations You Don’t Want to Miss at ASTRO 2023

Highlighting top abstracts for the annual radiation oncology conference

23-CNR-3964459-CQD-Hero-650×450 SBRT
New Study Highlights Potential Benefits of Ultrasound-Guided Prostate SBRT

Transperineal ultrasound a viable, non-invasive option for monitoring intra-fractional prostate motion

Ad